Don’t let the high cost of brand photodynamic therapy agent disrupt your ocular treatment. We help eligible patients access Visudyne (verteporfin IV) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Visudyne Patient Assistance Program helps eligible patients access this photodynamic therapy agent at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Visudyne PAP enrollment for a flat $69.95 per month — so you never face a gap in Visudyne therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Visudyne enrollment — so you never face a gap in your ocular photodynamic therapy.
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Bevacizumab compounded (alt) | ~$50/inj | Very cheap off-label alt |
| Retinal specialist center | ~$4,500/cycle | Save substantially |
| Ophthalmology infusion center | ~$4,000/cycle | Save substantially |
| Hospital outpatient | ~$5,000/cycle | Save substantially |
| 340B-eligible institution | ~$3,000/cycle | Save substantially |
| Anti-VEGF alt (Vabysmo) | ~$2,200/inj | First-line for CNV |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Visudyne — independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Visudyne Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Anti-VEGF is first-line for most AMD-related CNV. Visudyne PDT valuable for PCV, chronic central serous, and complex/refractory cases. Retinal specialist care essential.
Complete a simple eligibility form so our team can determine if you may qualify for Visudyne assistance.
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Once approved, your Visudyne is delivered through the assistance program while we manage refills and annual renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Visudyne:
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $3,000–$5,000/cycle per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Fixed $69.95/month — never changes regardless of retail price
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Visudyne assistance.
Visudyne is a photosensitizing agent activated by 689 nm laser light — combined with IV infusion of verteporfin followed by laser application to targeted retinal area, produces photochemical damage to abnormal blood vessels. Photodynamic therapy for choroidal neovascularization.
How It Works:
Choroidal neovascularization (CNV) — abnormal blood vessel growth beneath the retina — causes vision loss in age-related macular degeneration (AMD), pathologic myopia, ocular histoplasmosis, polypoidal choroidal vasculopathy (PCV), and other conditions. Anti-VEGF therapy targets VEGF-driven neovascularization and is now first-line for most CNV. Photodynamic therapy targets abnormal vessels via photochemical mechanism — complementary approach. Verteporfin is a photosensitizing agent. Following IV infusion, it accumulates in abnormal blood vessels (higher affinity for rapidly proliferating vascular endothelium). Application of 689 nm laser light activates verteporfin — generates reactive oxygen species causing photochemical damage to targeted vessels. Ideally selective closure of abnormal CNV without damaging normal retina. Now most commonly used in combination with anti-VEGF for polypoidal choroidal vasculopathy (PCV) and for chronic central serous retinopathy.
Form and Use:
Visudyne IV infusion over 10 minutes, followed by 689 nm laser application to targeted retinal area at 15 minutes after infusion. Retinal specialist procedure. Patient must avoid direct sunlight/bright light for ~48 hours after (photosensitivity). Multiple treatment cycles may be needed at 3-month intervals if CNV persists.
Generic Availability:
No generic Visudyne. Anti-VEGF therapy (first-line for most AMD-related CNV): bevacizumab (Avastin — off-label intravitreal, compounded, very cheap ~$50/dose), ranibizumab (Lucentis brand; Byooviz and Cimerli biosimilars), aflibercept (Eylea and Eylea HD 8mg brand; Yesafili and Opuviz biosimilars), faricimab (Vabysmo bispecific brand), brolucizumab (Beovu brand). Susvimo (ranibizumab port delivery implant — 6-month refills). PDT combined with anti-VEGF particularly valuable for PCV. Retinal specialist assessment for individualized approach. American Academy of Ophthalmology guidance.
Warnings:
Photosensitivity — patients must avoid direct sunlight, bright indoor light, and tanning beds for ~48 hours after infusion (skin photosensitivity from residual verteporfin can cause severe sunburn), infusion site pain and reactions, back pain during infusion (rare severe reaction — stop infusion), visual disturbances, embryo-fetal considerations, hypersensitivity reactions. Other: injection site pain, headache, nausea. Retinal specialist expertise. Comprehensive ophthalmology follow-up.
$3,000–$5,000 per PDT treatment cycle (drug + laser procedure). Anti-VEGF injections (first-line for most CNV) $50/dose (compounded bevacizumab) to $2,200/dose (Vabysmo brand). Cost comparison depends on treatment frequency and coverage.
Anti-VEGF therapy is first-line for most AMD-related choroidal neovascularization. Visudyne PDT remains valuable for: (1) polypoidal choroidal vasculopathy (PCV) — often combined with anti-VEGF for durable response, (2) chronic central serous retinopathy, (3) certain complex or refractory cases where anti-VEGF alone inadequate. Retinal specialist evaluation.
Verteporfin (photosensitizer) IV infusion — accumulates in abnormal choroidal blood vessels — 689 nm laser applied to targeted retinal area 15 minutes after infusion — activates verteporfin — reactive oxygen species cause photochemical vessel damage. Ideally selective closure of abnormal CNV without damaging normal retina.
Residual verteporfin in skin remains photosensitive for ~48 hours after infusion — direct sunlight, bright indoor light, or tanning beds can cause severe skin phototoxicity/sunburn. Avoid direct light exposure for 48 hours; wear protective clothing outdoors. Retinal specialist provides specific guidance.
Variable — depends on CNV response. Retreatment at 3-month intervals if persistent CNV on imaging. Combined with anti-VEGF for PCV commonly reduces retreatment burden. Retinal specialist individualizes plan.
PDT preserves value in specific retinal conditions — accessible therapy matters for vision. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.